These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 15245569

  • 1. CYP2C19 polymorphism and proton pump inhibitors.
    Klotz U, Schwab M, Treiber G.
    Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
    [Abstract] [Full Text] [Related]

  • 2. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U.
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [Abstract] [Full Text] [Related]

  • 3. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J.
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [Abstract] [Full Text] [Related]

  • 4. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [Abstract] [Full Text] [Related]

  • 5. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [Abstract] [Full Text] [Related]

  • 6. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 7. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
    Park SH.
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
    Kita T, Tanigawara Y, Aoyama N, Hohda T, Saijoh Y, Komada F, Sakaeda T, Okumura K, Sakai T, Kasuga M.
    Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K.
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [Abstract] [Full Text] [Related]

  • 20. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
    Furuta T, Shirai N, Sugimoto M, Nakamura A, Okudaira K, Kajimura M, Hishida A.
    Aliment Pharmacol Ther; 2005 Jul 01; 22(1):67-74. PubMed ID: 15963082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.